NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$37.5m

Last Updated

2021/05/13 22:13 UTC

Data Sources

Company Financials +

Executive Summary

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has InspireMD's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NSPR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: NSPR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-9.4%

NSPR

-3.6%

US Medical Equipment

-2.8%

US Market


1 Year Return

-61.7%

NSPR

32.9%

US Medical Equipment

49.4%

US Market

Return vs Industry: NSPR underperformed the US Medical Equipment industry which returned 32.9% over the past year.

Return vs Market: NSPR underperformed the US Market which returned 49.4% over the past year.


Shareholder returns

NSPRIndustryMarket
7 Day-9.4%-3.6%-2.8%
30 Day-46.6%-1.2%-2.3%
90 Day-75.6%-3.3%-1.3%
1 Year-61.7%-61.7%33.9%32.9%51.8%49.4%
3 Year-99.5%-99.5%66.8%62.9%57.5%47.6%
5 Year-100.0%-100.0%148.1%130.0%121.7%97.1%

Long-Term Price Volatility Vs. Market

How volatile is InspireMD's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InspireMD undervalued compared to its fair value and its price relative to the market?

0.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NSPR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NSPR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NSPR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: NSPR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NSPR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NSPR is good value based on its PB Ratio (0.6x) compared to the US Medical Equipment industry average (4.5x).


Future Growth

How is InspireMD forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

43.8%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NSPR's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if NSPR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NSPR's revenue (43.8% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: NSPR's revenue (43.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NSPR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has InspireMD performed over the past 5 years?

1.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NSPR is currently unprofitable.

Growing Profit Margin: NSPR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NSPR is unprofitable, but has reduced losses over the past 5 years at a rate of 1.4% per year.

Accelerating Growth: Unable to compare NSPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NSPR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.2%).


Return on Equity

High ROE: NSPR has a negative Return on Equity (-26.87%), as it is currently unprofitable.


Financial Health

How is InspireMD's financial position?


Financial Position Analysis

Short Term Liabilities: NSPR's short term assets ($46.3M) exceed its short term liabilities ($2.9M).

Long Term Liabilities: NSPR's short term assets ($46.3M) exceed its long term liabilities ($1.8M).


Debt to Equity History and Analysis

Debt Level: NSPR is debt free.

Reducing Debt: NSPR currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NSPR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NSPR has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8.5% each year


Dividend

What is InspireMD current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NSPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NSPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NSPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NSPR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NSPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Marvin Slosman (55 yo)

1.33yrs

Tenure

US$1,382,118

Compensation

Mr. Marvin L. Slosman has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman served as Chief Operating Officer for MEDCURA Incorporated from May 2019...


CEO Compensation Analysis

Compensation vs Market: Marvin's total compensation ($USD1.38M) is above average for companies of similar size in the US market ($USD536.35K).

Compensation vs Earnings: Insufficient data to compare Marvin's compensation with company performance.


Leadership Team

Experienced Management: NSPR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: NSPR's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 2614.8%.


Top Shareholders

Company Information

InspireMD, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InspireMD, Inc.
  • Ticker: NSPR
  • Exchange: NYSEAM
  • Founded: 2005
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$37.458m
  • Shares outstanding: 7.85m
  • Website: https://www.inspiremd.com

Number of Employees


Location

  • InspireMD, Inc.
  • 4 Menorat Hamaor Street
  • Tel Aviv
  • 6744832
  • Israel

Listings


Biography

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/13 22:13
End of Day Share Price2021/05/13 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.